• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

Experimental gene therapy results in full clinical reversal of X-linked SCID [Classics Series]

byAndrew Cheung, MD MBA
August 4, 2013
in General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Two patients with X-linked severe combined immunodeficiency (SCID) were treated with a retroviral-vector containing γc receptor for IL-2 with full clinical reversal after ten months.

2. No side effects were reported during the study period.

Original Date of Publication: April 28, 2000

Study Rundown: Prior to this experimental study, gene therapy was a theoretical concept confined to laboratory models of single gene diseases. Previous attempts to translate gene therapy into clinical application resulted in failure and most notably, in 1999, led to the death of Jesse Gelsinger from multiorgan system failure.

This study is notable because it showed the first definitive cure for X-linked severe combined immunodeficiency (SCID-X1) with clinical remission ten months after initial treatment. It was also notable as one of the first successful gene therapy trials. While cases of insertional mutagenesis due to the use of viral vector occurred in subsequent trials, this trial was considered a success in showcasing the potential of gene therapy as a viable clinical procedure. There are now several trials underway showing promise for treatment of SCID-X1 and adenosine deaminase deficiency, another deadly immune deficiency disease.

In summary, this study was a seminal paper in gene therapy that was originally published in 2000 in Science. Two patients with SCID-X1 exhibited full clinical remission of their disease and left protective isolation three months after treatment. At the time of publication, both patients were living at home for at least 10 months without any reported adverse effects.

RELATED REPORTS

Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B

Beremagene geperpavec improves wound healing in dystrophic epidermolysis bullosa

Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B

Please click to read study in Science

In-Depth [experimental study]: Two patients with SCID-X1, one 11 months-old (P1) and the other 8 months-old (P2), underwent ex vivo γc gene therapy. CD34+ cells were separated from bone marrow extracts and infected with a defective Moloney retrovirus containing the γc gene over the course of 3 days. Approximately 19 X 106 and 17 X 106 CD34+ cells/kg were infused into P1 and P2, respectively, without chemoablation. Transgene expression was 40% and 36 % for P1 and P2, respectively.

At 150 days after treatment, T-cell counts, including CD4+ and CD8+ cells, increased in both patients to values exceeding 2,800/µL from less than 500/µL in P1 and 1,300/µL in P2. Both patients manifested sustained function of their immune systems and left protective isolation at days 90 and 95 after gene therapy. At the time of publication, growth and psychomotor development was normal in both patients and no side effects were noted.

By Jose-Marc Techner, Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: gene therapyimmune deficiencyscid
Previous Post

Longer duration of breastfeeding improves childhood cognition

Next Post

Intrapartum maternal asthma linked to increased disease in children

RelatedReports

Study explores effects of daily iron supplementation in 2- to 5-year-olds
Chronic Disease

Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B

March 15, 2023
Video-based behavioral intervention benefits clinical skin examinations
Chronic Disease

Beremagene geperpavec improves wound healing in dystrophic epidermolysis bullosa

December 27, 2022
Separate panels of microRNAs may aid in early detection of pancreatic cancer
Chronic Disease

Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B

July 25, 2022
New genetic link in pulmonary arterial hypertension holds therapeutic promise
Chronic Disease

Valoctocogene roxaparvovec gene therapy efficacious for hemophilia A treatment

March 21, 2022
Next Post
Teen asthma controller medication adherence affected by risk tolerance

Intrapartum maternal asthma linked to increased disease in children

Wound surgical device found ineffective at infection control: ROSSINI Trial

2 Minute Medicine Rewind July 29 – August 4, 2013

Adolescent smoking heavily influenced by parents and siblings

Adolescent smoking heavily influenced by parents and siblings

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Metformin use may decrease risk of osteoarthritis development
  • Intensive blood pressure lowering by non-physician healthcare providers significantly reduces the risk of cardiovascular disease
  • Expectant management of patent ductus arteriosus noninferior to early ibuprofen use
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options